Talk:Idelalisib
Latest comment: 9 years ago by Rod57 in topic Expected pricing and revenue
| This is the talk page for discussing improvements to the Idelalisib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Idelalisib.
|
Expected pricing and revenue edit
"Zydelig's monthly price will be $7200" ... "$1.5 billion in annual sales by 2017."[1] - Rod57 (talk) 10:07, 1 August 2014 (UTC)